Sodium-Glucose Co-transporter-2 (SGLT-2) inhibitors are the only medications that have shown prognostic efficacy in all patients with heart failure regardless of diabatic status, or EF pertaining to HF hospitalizations and cardiovascular mortality [6, 36]. This evidence concerns the gene SLC5A2 and hydrops fetalis.